The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis - 8 years follow-up

Maturitas

Volumn 47, Issue 3, 2004, Pages 229-234

  Prelevic, Gordana M ^a,d   Markou, Athina ^a   Arnold, Amanda ^a   Bartram, Clive ^b   Puzigaca, Zarko ^c   Ginsburg, Jean ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Princess Grace Hospital   (United Kingdom)

^c Human Reproduction Cent   (Yugoslavia)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Osteopenia; Osteoporosis; Postmenopausal; Tibolone

Indexed keywords

TIBOLONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; ESTROGEN THERAPY; EVALUATION; FEMALE; FEMUR; HIP; HORMONE SUBSTITUTION; HUMAN; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; OSTEOPENIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; SAMPLE SIZE;

EID: 1442326207     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(03)00255-X     Document Type: Article

References (12)

1. Kicovic P.M., Cortes-Prieto J., Luisi M., et al. Placebo controlled cross-over study of the effects of Org OD 14 in menopausal women. Reproduction. 6:1982;81-91.
2. Benedek-Jaszmann L.J. Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women. Maturitas. (Suppl. 1):1987;25-33.
3. Genazzani A.R., Petraglia F., Facchinetti F., et al. Effects of OD14 on pituitary and peripheral β-endorphin in castrated rats and postmenopausal women. Maturitas. S1:1987;35-48.
4. Berning B., Kuijk C., Kuiper J.W., et al. The effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two year randomnized placebo controlled study. Bone. 19:1996;395-399.
5. Thiebaud D., Bigler J.M., Renteria S., et al. A three year study of prevention of postmenopausal bone-loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. Climacteric. 1:1998;202-210.
6. Rymer J., Robinson J., Fogelman I. Effects of eight years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporosis Int. 12:2001;478-483.
7. Lindsay C.P., Shaw R.W., Coelingh Bennink H.J.T., et al. The effect of add-back treatment with tibolone (Livial) on patients treated with gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil. Steril. 6592:1996;342-348.
8. Prelevic G.M., Bartram C., Wood J., Okolo S., Ginsburg J. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women. Gynecol. Endocrinol. 10:1996;413-420.
9. Pavlov P.W., Ginsburg J., Kicovic P.M., van der Schaaf D.B., Prelevic G., Coelingh Bennink H.J.T. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Gynecol. Endocrinol. 13:1999;230-237.
10. Studd J., Arnala I., Zambhere P., et al. Tibolone increases bone mass in women with previous fractures in a placebo controlled bicentre study. Osteoporosis Int. 6:(Suppl. 1):1996;230.
11. Ross P.D., et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann. Intern. Med. 114:1991;919-923.
12. Galagher J.C., Baylink D.J., Freeman R., McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled dose-finding studies. J. Clin. Endocrinol. Metab. 86:2001;4717-4726.